Podcasts about valneva

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into the dynamic shifts and breakthroughs shaping this ever-evolving industry. In a significant regulatory update, the resignation of FDA Commissioner Marty Makary has stirred discussions across the pharmaceutical landscape. Over his 13-month tenure, Makary faced considerable scrutiny for his controversial decisions, including the rejection of several rare disease drugs. This leadership change at the FDA may herald a period of uncertainty as the agency searches for new direction amidst criticisms and operational challenges. The implications are vast, potentially affecting drug approval processes and public health policies, making it crucial for stakeholders to watch closely how the agency adapts to this transition. Simultaneously, Takeda's announcement to lay off 4,500 employees marks a strategic move to streamline operations and focus on core competencies. This decision reflects a broader industry trend where companies are optimizing their structures to enhance financial health in a highly competitive market. The cost savings from this restructuring are expected to be substantial, allowing Takeda to pivot towards more sustainable business models and focus on areas that promise future growth. Eli Lilly and Novo Nordisk continue to lead in drug development with their GLP-1 receptor agonists. Both companies have reported promising data on early response and long-term weight loss maintenance in patients, positioning their therapies as pivotal in treating obesity. Eli Lilly's obesity treatments Foundayo (orforglipron) and Zepbound (tirzepatide) have shown sustained weight-loss maintenance in Phase 3 trials, reinforcing their efficacy in metabolic health interventions. These developments not only highlight the intense competition in the GLP-1 space but also underscore the potential impact on addressing global obesity challenges effectively. The strategic landscape of mergers and acquisitions is also evolving with Merck KGaA's announcement to bolster its pipeline through strategic M&A activities. This move is emblematic of an industry-wide strategy where companies seek external innovation to fill pipeline gaps, ensuring sustained growth and competitiveness. In a related vein, BioMarin's $4.8 billion acquisition of Amicus Therapeutics signifies a firm commitment to addressing unmet needs in rare diseases, illustrating how consolidation can enhance capabilities in niche markets with significant potential. In vaccine development, Valneva's decision to reduce its workforce by up to 15% highlights ongoing challenges in the sector, particularly for travel-related vaccines affected by global market trends. This restructuring is indicative of the volatility faced by companies as they adapt strategies for long-term sustainability amidst shifting consumer behaviors. Pfizer's expansion into Europe with its hemophilia treatment Hympavzi marks a critical regulatory milestone, broadening its market presence and offering expanded therapeutic options for patients. This approval not only strengthens Pfizer's foothold in the hemophilia market but also exemplifies the global reach of innovative treatments. Technological integration continues to revolutionize R&D processes, as evidenced by AstraZeneca's licensing agreement with Owkin for AI capabilities. This partnership aims to harness AI-driven insights for drug discovery, showcasing how technology is reshaping traditional research methodologies and enhancing efficiency. Similarly, advancements in AI-powered diagnostics are evidenced by Boehringer Ingelheim's collaboration with Brainomix in pulmonary fibrosis imaging, reflecting broader trends towards personalized medicine through precise disease characterization. Kyverna Therapeutics is advancing in cell therapy with Support the show

Broadcast from KSQD, Santa Cruz on 5-07-2026: Dr. Dawn debunks the 1971 "220 minus age" maximum heart rate formula, noting a 2025 study found individual predictions were off by up to 20 beats per minute. She recommends the Tanaka equation (208 minus age) times 0.7, but emphasizes tracking improvement trends rather than absolute numbers. ConsumerLab testing found Safe Catch Wild Elite Pure Tuna and Wild Ahi Yellowfin Tuna had no detectable mercury, prompting Dr. Dawn to reconsider eating tuna after years of avoidance due to concerns about mercury bioaccumulation and its effects on nerve microtubules. A meta-analysis of 115 studies involving 55,000 men found limiting ejaculation before IVF leads to increased sperm DNA damage and poorer motility. Clinical trials showed 46% IVF pregnancy rates with less than 48 hours abstinence versus 36% with longer periods. A personalized mRNA vaccine for pancreatic cancer showed striking results: of 16 patients whose tumors were surgically removed, half produced killer T-cells targeting cancer, and seven of those eight remain alive six years later. Pfizer and Valneva's Lyme disease vaccine reduced infection by over 70% in a trial of 9,400 people ages five and up. Nearly half a million Americans contract Lyme annually, and chronic infection can cause nervous system damage and chronic fatigue. Dr. Dawn explores the gray-market peptide ecosystem, where compounds are sold as "research chemicals" with wink-and-nod marketing. A 2018 Belgian study found purity levels ranging from 5% to 99.9%, with some samples containing arsenic, lead, or industrial contaminants. A study of 450 people found that blocking smartphone internet access for two weeks improved sustained attention equivalent to reversing 10 years of age-related cognitive decline, with depression symptom improvements comparable to cognitive behavioral therapy. A multi-country study of 241 unresponsive patients found that 25% showed brain activity indicating consciousness when asked to imagine playing tennis during advanced brain scans. Scientists call this cognitive motor dissociation, and by some estimates tens of thousands of Americans may be misdiagnosed. Chinese researchers grew functional adrenal cortex organoids that responded to pituitary hormones and produced cortisol when transplanted into mice. They also introduced genetic mutations to create organoid models of Cushing's syndrome for drug testing. A Science paper identified the neural pathway connecting psychological stress to eczema flare-ups: sympathetic neurons from the stellate ganglion recruit eosinophils to the skin. Researchers traced the pathway using pseudo-rabies virus injected into skin. Mouse studies showed prenatal stress causes elevated corticosterone in amniotic fluid, which activates fetal mast cells derived from the yolk sac. Offspring develop eczema-like lesions in areas receiving mechanical stimulation, but symptoms resolve around 24 weeks when bone marrow-derived mast cells replace the activated ones. Callers ask about CBN side effects. Dr. Dawn explains cannabinoids prolong anandamide's calming effects by slowing its breakdown, and considers 30-45mg over a night reasonable, but cautions against escalating doses given limited research.

Confira os destaques do Jornal da Manhã desta terça-feira (05): O empresário Leonardo Berganholi, de 50 anos, morreu após não resistir aos ferimentos causados pela queda de um avião monomotor que atingiu um prédio residencial em Belo Horizonte. O acidente também deixou outras vítimas: o piloto Wellington Oliveira e Fernando Moreira Souto morreram no local. Já Arthur Schaper Berganholi, filho do empresário, e Hemerson Cleiton Almeida Souto foram socorridos em estado grave e encaminhados ao Hospital João XXIII. A equipe econômica anunciou mudanças nas regras dos empréstimos consignados para servidores públicos, aposentados e pensionistas. A principal alteração é a redução da margem de consignação de 45% para 40% da renda mensal. Segundo o governo, o limite continuará diminuindo gradualmente, com queda de dois pontos percentuais por ano, até atingir 30% em cinco anos, com o objetivo de reduzir o nível de endividamento da população. A Agência Nacional de Vigilância Sanitária autorizou a fabricação no Brasil da vacina contra chikungunya desenvolvida pelo Instituto Butantan em parceria com a farmacêutica Valneva. Com a decisão, o imunizante XCHIQ passa a ser produzido no país e poderá ser incorporado ao Sistema Único de Saúde. A vacina já havia sido aprovada em 2025, mas agora o Butantan é oficializado como local de produção, ampliando a capacidade nacional e mantendo os padrões de qualidade, segurança e eficácia. O presidente Luiz Inácio Lula da Silva sancionou com vetos a lei que endurece as penas para crimes como furto, roubo, estelionato, receptação e roubo seguido de morte. A norma também amplia punições para crimes virtuais, incluindo golpes pela internet, fraudes bancárias e furtos de celulares. Apesar do avanço, o presidente vetou o trecho que aumentava a pena de roubo com violência e lesão grave para até 24 anos, mantendo ajustes na legislação penal. O Ministério da Defesa da Rússia anunciou que o país realizará um cessar-fogo unilateral com a Ucrânia a partir desta quarta-feira (06). A decisão, determinada pelo presidente Vladimir Putin, foi divulgada por meio de aplicativo oficial e representa uma pausa temporária nos combates, em meio ao conflito que segue em curso na região. O presidente Luiz Inácio Lula da Silva deve se reunir com o presidente dos Estados Unidos, Donald Trump, nesta quinta-feira (07), na Casa Branca, em Washington. O encontro está previsto para a manhã, seguido de um almoço oficial, e ocorre em meio a uma crise diplomática entre os dois países envolvendo a prisão e soltura do ex-deputado Alexandre Ramagem em território americano. O deputado estadual Thiago Rangel (Avante) foi preso nesta terça-feira (05) durante a 4ª fase da Operação Unha e Carne, deflagrada pela Polícia Federal. A ação investiga fraudes em contratos de compra de materiais e serviços, incluindo obras na Secretaria Estadual de Educação do Rio de Janeiro. Ao todo, foram expedidos 7 mandados de prisão preventiva e 23 de busca e apreensão em diferentes cidades do estado. Segundo a PF, as apurações indicam direcionamento de contratações para empresas ligadas ao esquema, com base em investigações iniciadas em fases anteriores da operação. O almirante Brad Cooper, chefe do Comando Central dos Estados Unidos, afirmou que helicópteros militares americanos afundaram seis embarcações iranianas que teriam como alvo navios civis no Estreito de Ormuz. Segundo ele, forças iranianas lançaram mísseis, drones e ataques com pequenas embarcações, mas todas as ameaças foram neutralizadas. Os EUA também afirmam ter aberto um corredor seguro na região, livre de minas, para garantir a passagem de navios comerciais, em meio a tensões que colocam à prova o cessar-fogo entre os países. Essas e outras notícias você acompanha no Jornal da Manhã. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dans ce numéro du Journal des biotechs, Jamila El Bougrini revient sur la situation de Valneva et DBV Technologies et elle analyse en détail l'intérêt des big pharma américaines sur les biotechs avec une vague récente d'acquisitions pour plusieurs milliards de dollars.L'entretien est consacré à Laurent Levy. Le président du directoire fait le point complet sur la situation de Nanobiotix entre avancées cliniques, résultats financiers et rumeurs boursières insistantes. Hébergé par Audion. Visitez https://www.audion.fm/fr/privacy-policy pour plus d'informations.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of remarkable advancements and challenges shaping these dynamic sectors. AstraZeneca has reported promising results with an immunotherapy combination involving Imfinzi (durvalumab) and Imjudo (tremelimumab) for treating locoregional liver cancer. This combination has demonstrated a significant progression-free survival benefit, potentially setting a new standard in liver cancer treatment. The success of this regimen highlights the critical role of immunotherapies in oncology, offering new hope for patients with cancers that have been historically difficult to treat. Turning to regulatory news, Eli Lilly's new GLP-1 receptor agonist pill, Foundayo, has received FDA approval. This marks a significant milestone as it's the first new molecular entity approved under the FDA's National Priority Voucher Program. Foundayo's approval intensifies the competition in the obesity treatment market, challenging Novo Nordisk's established position with Wegovy. Analysts forecast a major rollout for Foundayo, predicting over 5 million prescriptions by 2026. This advancement underscores the increasing focus on addressing obesity, a critical global health challenge. In geopolitical news, former U.S. President Donald Trump is reportedly considering imposing a 100% tariff on certain pharmaceutical imports from non-Most Favored Nation countries. Such a policy could significantly impact international pharmaceutical trade and supply chains, forcing companies to reevaluate their global manufacturing and distribution strategies. In vaccine development news, a Belgian court has ordered Poland and Romania to pay Pfizer $2.2 billion over contested COVID-19 vaccine doses, underscoring the complexities of international vaccine agreements and their financial ramifications during the pandemic. Conversely, Pfizer and BioNTech have halted their US Phase 3 trial for the Comirnaty COVID-19 vaccine due to recruitment challenges. This reflects ongoing difficulties in maintaining participant engagement for booster studies post-pandemic. On the clinical trial front, Valneva's Lyme disease vaccine program with Pfizer remains a topic of interest despite missing its primary endpoint in Phase 3 trials. Valneva's CEO remains optimistic about its regulatory future, framing it as a matter of negotiation. This situation highlights the intricate nature of clinical trial outcomes and regulatory negotiations. Meanwhile, Gilead Sciences has faced setbacks with its HIV drug pipeline due to an ongoing FDA clinical hold on a mid-stage trial. This incident underscores the challenges companies encounter while navigating regulatory hurdles to ensure drug safety. In other industry trends, there's an increased reliance on pharmacovigilance outsourcing to enhance efficiency within pharmaceutical companies. This allows firms to concentrate more on core activities impacting patient care and drug innovation directly. The industry also saw exciting advancements in radioligand therapy, which holds promise for targeting up to 80% of cancers with precision therapies. Such developments illustrate how understanding biological pathways can lead to significant breakthroughs in cancer treatment paradigms. In business developments, Axsome Therapeutics has partnered with Takeda for Balipodect, a schizophrenia asset involving undisclosed payments. This partnership highlights the trend towards strategic collaborations in neurological disorders aimed at fostering therapeutic innovation. Furthermore, Zai Lab and Amgen are collaborating on a global Phase 1b trial focusing on small cell lung cancer using antibody-drug conjugates and bispecific T-cell engagers. This research emphasizes growing interest in precision oncology treatments offering targeted therapeutic oSupport the show

On this week's episode, Grace Colón, Josh Schimmer, Eric Schmidt, and Brian Skorney open with a look at the macro backdrop. With market volatility and interest rate uncertainty, the hosts agree the macro is still “driving the bus,” tempering what might otherwise be stronger bullish sentiment. Even so, biotech continues to demonstrate relative resilience – XBI holding up better than the broader market – reinforcing the view that investors still want to own biotech. In deals, the co-hosts discuss Gilead's more than $2 billion purchase of Ouro Medicines for its autoimmune disease drug, Merck's $6.7 billion takeover of Terns to bolster its oncology pipeline, and Novartis' deal for Exellergy to strengthen its allergy portfolio. The conversation shifts to regulatory news, including the approval of Denali's Hunter syndrome drug, Avlayah, which comes shortly after the FDA rejected Regenxbio's gene therapy for the same condition. Other recent rare disease approvals are noted, with the group interpreting them as signs of slightly increased regulatory flexibility following leadership changes, though uncertainty remains across the health agencies.  The episode concludes with recent data news and market reactions from Sarepta and Arrowhead, Maze versus Vertex in kidney disease, Beam's data in AATD, Lyme disease vaccine data from Pfizer and Valneva, and a preview of data to be presented at AAD. *This episode aired on March 27, 2026. 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of transformative events that are shaping the future of drug development and patient care.Beginning with Novartis, the company has made a strategic investment of approximately $480 million to expand its manufacturing and R&D capabilities in China. This move aligns with the broader trend of global pharmaceutical companies seeking to bolster their presence in one of the fastest-growing healthcare markets. China's demand for innovative healthcare solutions is on the rise, making it a critical region for expansion as companies look to tap into new opportunities for growth.In drug development, Insmed's Arikayce is on the verge of a significant label expansion following promising results from its Phase 3 clinical trials. This development could provide a new lifeline for patients dealing with Mycobacterium avium complex (MAC), offering more robust treatment options and improving patient outcomes in this challenging area of infectious disease management.The U.S. FDA is actively engaging stakeholders to gather feedback on the National Priority Voucher review pathway. This initiative is designed to expedite drug reviews for critical therapies, although it has stirred debate concerning its impact on regulatory standards and market dynamics. The agency's commitment to transparency is evident in its approach to involving public opinion in shaping these policies, indicating an openness to adapt regulatory frameworks that can better support innovation.In oncology, competition is heating up in the non-small cell lung cancer (NSCLC) arena. Dizal's Zegfrovy has shown promising Phase 3 trial results, positioning it as a strong competitor against Johnson & Johnson's Rybrevant. These findings not only highlight Zegfrovy's potential efficacy but also offer hope for patients battling this difficult-to-treat subtype of lung cancer.On the regulatory front, the FDA has mandated updates to the labels of common Parkinson's medications such as levodopa and carbidopa, following concerns about seizure risks linked to vitamin B6 deficiency. This decision underscores the agency's focus on safety monitoring and emphasizes the importance of vigilance by healthcare providers when prescribing these treatments.Meanwhile, Apogee Therapeutics has released compelling Phase 2 data for its anti-IL-13 antibody targeting eczema. This new contender poses a significant threat to established players like Eli Lilly and Sanofi, with analysts predicting substantial market impact due to its enhanced efficacy. As competition intensifies, Apogee's candidate might just redefine treatment landscapes within dermatology.In vaccine development, Pfizer and Valneva are continuing their efforts despite challenges in their Phase 3 Lyme disease vaccine trial caused by unexpectedly low incidence rates. Their perseverance reflects a strategic commitment to addressing unmet medical needs in infectious diseases—a testament to their resolve in enhancing public health outcomes.Sanofi's re-entry into the T-cell engager space through collaboration with Kali Therapeutics marks another significant move in immuno-oncology. By acquiring a trispecific antibody at an early stage, Sanofi aims to harness cutting-edge immunotherapies that effectively target cancer cells by leveraging the body's natural defenses.Cybersecurity has also emerged as a pivotal concern following disruptions at Stryker due to cyberattacks. The company's rapid recovery highlights the critical importance of cybersecurity measures in maintaining seamless healthcare delivery systems—a reminder that technological resilience is as crucial as scientific innovation.These developments reflect an era marked by rapid innovation and evolving regulatory landscapes within the pharmaceutical and biotech sectors.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the latest transformative movements within this dynamic arena, focusing on pivotal acquisitions, technological integrations, and regulatory updates shaping the future of healthcare solutions.Starting with strategic corporate maneuvers, Pfizer recently divested its 11.7% stake in GSK's ViiV Healthcare, a prominent player in HIV treatments. This $1.875 billion sale to Shionogi reflects Pfizer's strategy to offset anticipated revenue declines while fortifying Shionogi's position in the HIV treatment landscape. For GSK, the transaction brings a $250 million special dividend, highlighting competitive realignments as companies optimize portfolios in the lucrative HIV market.In another significant investment, Roche plans a $2 billion expansion at Genentech's North Carolina site to produce next-generation drugs targeting metabolic conditions like obesity. This move aligns with Roche's strategy to capture a growing market segment driven by the rising prevalence of obesity-related health issues globally.Exelixis is aggressively pursuing its ambition to become a top contender in the U.S. solid tumor market. With its flagship drug Cabometyx at the forefront, Exelixis anticipates promising Phase 3 results for new blockbuster candidates, underscoring its robust oncology-focused growth strategy. This field continues to attract substantial investment due to an unmet need for effective cancer therapies.Turning to regulatory landscapes, a landmark decision is anticipated from the U.S. Supreme Court regarding the "skinny label" dispute between Hikma Pharmaceuticals and Amarin over generic Vascepa. This case could reshape patent litigation strategies and impact how generics are marketed against branded drugs, influencing future industry practices.Meanwhile, AbbVie and Genmab face reassessment after their Phase 3 trial for Epkinly in diffuse large B-cell lymphoma failed to meet survival endpoints. This outcome may prompt a strategic pivot towards pipeline diversification or new partnerships in oncology.Valneva recently withdrew its chikungunya vaccine Ixchiq from U.S. consideration following an FDA investigation into adverse events, highlighting the complex regulatory environment surrounding vaccine approvals and safety protocols. In contrast, Bristol Myers Squibb's collaboration with Microsoft aims to expedite lung cancer diagnosis using AI technology, reflecting a broader trend of integrating digital health solutions into drug development and patient care.GSK's acquisition of Rapt Therapeutics for $2.2 billion further emphasizes its commitment to innovative immunotherapies addressing unmet needs in food allergy treatments. This move aligns with trends towards personalized medicine as companies explore novel mechanisms for targeted therapeutic interventions.In scientific breakthroughs, Merck and Moderna report sustained efficacy in their cancer vaccine collaboration, showing a 49% reduction in melanoma risk over five years when combined with Keytruda. This sets a strong precedent for developing combination therapies that enhance long-term cancer treatment outcomes.Pfizer's $530 million agreement with Novavax seeks to leverage adjuvant technology across its vaccine programs, underscoring Pfizer's commitment to innovation amid ongoing competition within the vaccine market.Oncology advancements continue as AstraZeneca secures full rights to an armored CAR-T therapy from Abelzeta for $630 million. Targeting glypican-3 proteins associated with certain cancers, this acquisition highlights AstraZeneca's push into advanced cell therapies that promise revolutionary cancer care solutions.Beyond these corporate strategies, ARPA-H envisions transcending traditional vaccine technologies through innovative solutions that could render vSupport the show

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll explore the latest advances and strategic moves shaping the industry, providing you with insights into how these developments might influence drug development and patient care.The pharmaceutical and biotech sectors are currently experiencing a wave of transformative changes. A significant development is the trade agreement between the United States and the United Kingdom, which excludes medicines from import tariffs. This strategic move, orchestrated by the Trump administration, is set to reduce costs and bolster investments in pharma sectors across both nations. By enhancing market accessibility, it aims to stimulate cross-border investment in pharmaceutical research and production.On the clinical front, Eli Lilly is making headlines by joining Novo Nordisk in reducing self-pay prices for its GLP-1 receptor agonist, Zepbound. This reflects a broader industry trend towards patient-centric pricing models aimed at improving affordability. With healthcare costs on the rise, these measures could ease financial burdens for patients requiring long-term medication regimens.Regulatory updates are also making waves, with the FDA planning stricter vaccine regulations under Dr. Vinay Prasad's leadership at the Center for Biologics Evaluation and Research (CBER). These updates come amid concerns over vaccine safety during COVID-19-related incidents, underscoring a commitment to maintaining public trust in vaccines. Regulatory scrutiny continues as Prasad focuses on COVID-19 vaccine safety in children amid reports linking 10 child deaths to vaccines via VAERS—emphasizing challenges interpreting safety data while highlighting the need for robust methodologies ensuring reliable causality conclusions.In corporate restructuring news, Valneva is streamlining its operations by closing a site and eliminating 30 roles. This move highlights an industry focus on optimizing resources to bolster vaccine development pipelines. Meanwhile, Microsize and Schedio's acquisition of Lonza's Swiss micronization plant underscores ongoing investments in advanced manufacturing technologies critical for high-quality pharmaceuticals.In ophthalmology, Belite Bio is advancing with promising Phase 3 results for tinlarebant in treating Stargardt disease—a rare genetic eye disorder. This success positions Belite to file for FDA approval, potentially expanding treatment options for this underserved patient population. Such advancements in targeted therapies emphasize the need for ongoing research in genetic disorders.Regeneron is betting $150 million on Tessera's gene writing technology targeting alpha-1 antitrypsin deficiency (AATD). This collaboration highlights the industry's growing interest in gene therapy as a frontier for treating rare diseases, marking a shift towards precision medicine where tailored genetic interventions offer hope for previously untreatable conditions. Regeneron's strategic move investing $275 million partnering with Tessera exploring gene editing capabilities—focusing on TSRA-196 targeting the SERPINA1 gene linked to AATD showcases potential advancing therapeutic options for genetic disorders through gene editing technologies offering new disease treatment avenues.AI-driven platforms were spotlighted at RSNA 2025 by industry leaders such as GE Healthcare, Philips, and Siemens. These innovations promise to revolutionize radiological workflows by enhancing diagnostic accuracy and operational efficiency through AI integration. As AI continues to permeate healthcare technologies, its potential to transform diagnostic processes marks a significant leap towards personalized medicine.Akebia Therapeutics' acquisition ofSupport the show

Valneva now has three commercialized vaccines, and a Lyme disease candidate in Phase 3. Philip quizzes CEO Thomas Lingelbach about everything. They also discuss the current political turbulence with vaccines, especially in the US, and how it is impacting the industry.⭐️ ABOUT THE SPEAKERA veteran in the development of more than ten vaccines, Thomas has spent over 30 years in the vaccine space and has served in senior roles at the companies Intercell, Novartis and Chiron. Thomas was with Intercell since 2006 and was the CEO when the company merged with Vivalis to form Valneva in 2013.

“We invest emotionally and intellectually in their journey—when their product reaches patients, that's our success too.”Janet Hoogstraate, CEO of NorthX Biologics, brings ~30 years of pharmaceutical experience spanning from preclinical development to GMP production for marketed products, with leadership roles at Valneva and AstraZeneca. Her experience from both the CDMO and sponsor sides contributes to NorthX's approach to developing advanced biologics in extended collaboration with the innovative product companies.The contract development and manufacturing organization (CDMO) landscape is evolving beyond transactional relationships toward integrated partnerships. In this podcast, recorded at Nordic Life Science Days (NLSDays) in Gothenburg, Janet outlines how CDMOs can function as strategic partners rather than service vendors, sharing insights from an interactive workshop on growing CDMO relationships alongside clinical development.Read more.

On Aug. 25, the FDA informed the public that the agency officially suspended its approval for Valneva's Ixchiq vaccine.Ixchiq is a vaccine for Chikungunya, a mosquito-borne disease. The vaccine was initially approved to be administered in the United States in November 2023, under the FDA's fast-tracked accelerated approval pathway.Let's go through what the data showed, as well as why the FDA decided this move to stop the vaccine was necessary.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.AbbVie has acquired Gilgamesh Pharmaceuticals for $1.2 billion, focusing on neurology and depression treatments. This move follows AbbVie's previous failure with Emraclidine in schizophrenia treatment. The biotech industry's IPO stalemate appears to be ending, with Lb Pharma planning an IPO to fund a phase III-ready schizophrenia asset. The FDA has pulled Valneva's chikungunya shot from the market due to safety concerns, and several obesity drugs have failed to make it to market. Meanwhile, Arnatar is working on advancing RNA therapies beyond silencing.In other news, the disappointment of oral obesity therapies is discussed, with Novo emerging as a leader in the field. Trials for Eli Lilly's Orforglipron and Viking Therapeutics' VK2735 were underwhelming, leading to increased interest in weight loss pills in low- and middle-income countries. Capricor Therapeutics plans to fight FDA rejection of its DMD cardiomyopathy treatment, while a study in JAMA contradicts claims of corruption in vaccine advisory committees. Updates on cancer, cell and gene therapy are also provided.Stay tuned for more updates and feel free to suggest topics for future coverage.

The biologics external manufacturing panel at CDMO Live 2025, sponsored by BSP Pharmaceuticals, brought together industry leaders to tackle the key challenges in scaling biological manufacturing amid geopolitical tensions, capacity constraints and evolving partnership models.The panel featured Olaf Birkenmeier, Head of External Manufacturing at Polpharma Biologics; Julien Laizé, Director of External Manufacturing CTM at Valneva; Catherine Seigneur, Senior Director of External Manufacturing Business Lead at UCB; and Giorgio Salciarini, Head of Sales - Technical Business Development at BSP Pharmaceuticals.Download the full CDMO Live Report

“In Big Pharma, innovation is often stifled because the bureaucracy and mindset completely kills creativity and intuition needed for discovery. That's why they now prefer to allocate their early-phase resources to smaller biotechs,” explains Julien Laizé, sharing candid insights about the delicate balance between innovation and compliance in vaccine manufacturingJulien Laizé serves as Director of External Manufacturing CTM at Valneva, a French-based specialty vaccine company developing and commercialising vaccines for infectious diseases. With previous roles at Novo Nordisk and Eli Lilly, Julien brings unique perspectives on managing external manufacturing across both big pharma and biotech environments, particularly in navigating the tension between innovation and regulatory compliance.Ahead of CDMO Live next week, Julien shares his experiences in fostering innovation while maintaining rigorous quality standards, and explains why the industry's greatest discoveries often come from embracing calculated risks.Listen to the full episode here and join Julien and other ExM leaders at CDMO Live 2025, 7-8 May, Rotterdam.

Com a aprovação, ontem, da primeira vacina contra chikungunya pela Agência Nacional de Vigilância Sanitária (Anvisa), o Instituto Butantan já iniciou o processo de importação do imunizante. Depois, numa segunda etapa, deve começar a produção nacional. O imunizante, de dose única, foi autorizado a ser aplicado na população de 18 a 65 anos. A vacina foi desenvolvida pela farmacêutica austríaca Valneva e o registro foi feito em parceria com o Instituto Butantan. Segundo a Anvisa, estudos clínicos com adultos e adolescentes mostraram que a vacina ajuda o corpo a induzir a produção de anticorpos neutralizantes contra o vírus da chikungunya. Em entrevista à Rádio Eldorado, o diretor de Assuntos Regulatórios, Qualidade e Ensaios Clínicos do Instituto Butantan, Gustavo Mendes, afirmou que inicialmente serão recebidas 400 mil doses, mas destacou que o Butantan já se prepara para produzir de 5 milhões a 10 milhões de doses por ano e faz estudos clínicos para expandir as faixas etárias atingidas. A chegada do novo imunizante à população ainda depende de aprovação da Comissão Nacional de Incorporação de Tecnologias no Sistema Único de Saúde (Conitec).See omnystudio.com/listener for privacy information.

A Anvisa aprovou o pedido para registro definitivo da vacina contra a chikungunya encaminhado pelo Instituto Butantan, em parceria com a empresa farmacêutica Valneva. O imunizante está autorizado a ser aplicado no país na população acima de 18 anos.O Giro de Notícias mantém você por dentro das principais informações do Brasil e do mundo. Confira mais atualizações na próxima edição.

Depuis le début de l'année 2025, plus de 27 500 personnes ont déjà été officiellement contaminées le chikungunya, et plus de 6 300 cas ont été enregistrés la semaine dernière sur l'île de La Réunion. Transmis par le moustique tigre, le virus provoque de la fièvre, de fortes douleurs articulaires et parfois des éruptions cutanées. Si les symptômes durent normalement quelques jours, il peut, notamment pour les personnes fragiles, âgées ou atteintes de comorbidité, entraîner la mort. Pour éviter les cas les plus graves, une nouvelle étape vient d'être franchie dans la lutte contre le chikungunya avec le lancement d'une campagne de vaccination. Depuis le 7 avril à La Réunion, les pharmaciens et médecins peuvent vacciner contre le chikungunya ; 40 000 premières doses ont été livrées, comme à la pharmacie de La Trinité à Saint-Denis. « Alors ça, c'est le vaccin  IXCHIQ. C'est le vaccin qui est préconisé pendant l'épidémie de chikungunya », explique Paul Dumas, pharmacien. Face à cette campagne inédite, il faut rassurer autour du tout nouveau vaccin créé par le labo franco-autrichien Valneva, expliquer par exemple qu'il n'a rien à voir avec le fonctionnement de l'ARN messager utilisé contre le Covid-19. « C'est un virus de chikungunya atténué qu'on injecte au patient, et le patient va développer des anticorps contre le chikungunya. Et après, il sera protégé par rapport à ce virus. »Le vaccin protège au bout de 15 jours après l'injection et pour au moins trois ans. Malgré tout, certaines personnes hésitent encore, comme Bernadette : « Je veux parce que j'ai un problème cardiaque, et en même temps, je ne veux pas, car j'ai fait trop de vaccins ces derniers temps. Mon mari va le faire. Lui, il attend ça avec impatience. Il est diabétique, c'est sûr qu'il va le faire. »Se faire vacciner par mesure de préventionPourtant, les dix doses quotidiennes réservées dans chaque pharmacie aux plus de 65 ans souffrant de comorbidités trouvent preneurs. Patrick a 76 ans, de l'asthme et un problème aux reins. Il a donc saisi l'occasion de cette injection gratuite avec une ordonnance : « C'est par sécurité. C'est idiot de risquer de tomber malade pour une absence de vaccin. Il existe, alors autant le faire. J'ai mes petits voisins qui ont été contaminés. Ils étaient malades pendant trois jours avec 39°C de fièvre. Je n'ai pas envie de vivre ça. Moi, je crois à la vaccination. »Et pour se donner du courage, Patrick est venu avec Cathy : « J'ai 61 ans, je suis la conjointe de Patrick et je voulais me faire vacciner en même temps. Même si je ne suis pas éligible au vaccin, puisque je suis trop jeune et je n'ai pas de comorbidité. Mais bon, j'ai payé mon vaccin et je me fais vacciner en même temps que lui pour éviter de l'attraper éventuellement avant qu'on soit immunisé tous les deux. C'est une sécurité pour nous deux. Et puis bon, j'ai appris que pour les femmes enceintes, c'est compliqué. On a une fille qui va peut-être être enceinte, alors je n'ai pas envie de ramener ça dans son jardin. Je crois que c'est une sécurité pour tout le monde. »Le vaccin est coûteux pour ceux qui ne sont pas pris en charge. Prix de vente conseillé : 190 €. Une injection qui, pour l'heure, n'est pas recommandée aux femmes enceintes et aux enfants.À lire aussiL'épidémie de Chikungunya s'intensifie à La Réunion, les autorités annoncent une campagne de vaccination

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Julien Laizé, Director External Manufacturing CTM at Valneva. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Julien, covering: Comparative views of being externally outsourced in large pharma's R&D vs a more action-oriented, small-med pharma company Taking us behind the scenes into in-housing vs outsourcing manufacturing decisions and CDMO identification... Why the selection process is becoming more and more challenging for buyers The importance of reputation and track record for CDMOs, and the value of being known as a specialist How do geopolitical issues and macro uncertainty play into the planning of external manufacturing?   Julien Laizé is a French/Italian executive with extensive and international experience in the vaccines and biologics industry. A Doctor of Pharmacy, Julien spent time at Siemens Healthineers, Novo Nordisk and Eli Lilly before joining Valneva, a specialty vaccine company focused on developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Tue, 04 Mar 2025 11:43:00 +0000 https://jungeanleger.podigee.io/2057-wiener-borse-party-854-atx-deutlich-im-minus-dosko-goes-frequentis-valneva-goes-wienerberger-ktm-goes-neumeister 7656bb296ef26d6e5f0433f5f385ba4f Die Wiener Börse Party ist ein Podcastprojekt für Audio-CD.at von Christian Drastil Comm..Unter dem Motto „Market & Me“ berichtet Christian Drastil über das Tagesgeschehen an der Wiener Börse. Inhalte der Folge #854: - ATX am Faschingsdienstag deutlich im Minus - Zahlen von Bawag, News zu Frequentis, Pierer Mobility, BKS, Research zu Erste Group, FACC, Flughafen Wien - Valneva goes Wienerberger - Vintage: SBO, Marinomed, Warimpex - Unsympathler-Spoiler - weiter gehts im Podcast Links: - Börsepeople morgen Stefan Ebenberger http://www.audio-cd.at/people - kapitalmarkt-stimme.at daily voice Playlist auf spotify: http://www.kapitalmarkt-stimme.at/spotify - kapitalmarkt-stimme-Jingle-Mann Steve Kalen: https://open.spotify.com/intl-de/artist/6uemLvflstP1ZerGCdJ7YU - Stockpicking Österreich: https://www.wikifolio.com/de/at/w/wfdrastil1? - http://www.boersentag.at ATX aktuell: https://www.wienerborse.at/indizes/aktuelle-indexwerte/preise-mitglieder/??ISIN=AT0000999982&ID_NOTATION=92866&cHash=49b7ab71e783b5ef2864ad3c8a5cdbc1 Die 2025er-Folgen der Wiener Börse Party (Co-verantwortlich Script: Christine Petzwinkler) sind präsentiert von Wienerberger, CEO Heimo Scheuch hat sich ebenfalls unter die Podcaster gemischt: https://open.spotify.com/show/5D4Gz8bpAYNAI6tg7H695E . Im Q1 ist die ÖBAG der Co-Presenter. Risikohinweis: Die hier veröffentlichten Gedanken sind weder als Empfehlung noch als ein Angebot oder eine Aufforderung zum An- oder Verkauf von Finanzinstrumenten zu verstehen und sollen auch nicht so verstanden werden. Sie stellen lediglich die persönliche Meinung der Podcastmacher dar. Der Handel mit Finanzprodukten unterliegt einem Risiko. Sie können Ihr eingesetztes Kapital verlieren. Und: Bewertungen bei Apple (oder auch Spotify) machen mir Freude: http://www.audio-cd.at/spotify http://www.audio-cd.at/apple 2057 full no Christian Drastil Comm.

Sat, 01 Feb 2025 07:42:00 +0000 https://jungeanleger.podigee.io/1969-wiener-borse-party-832-atx-tr-auf-weg-9000er-close-schade-um-valneva-bzw-ca-immo-und-rwt-buddy-sounds-zum-schluss cb730333a0bda26557fc85fdccb8d48f Die Wiener Börse Party ist ein Podcastprojekt für Audio-CD.at von Christian Drastil Comm..Unter dem Motto „Market & Me“ berichtet Christian Drastil über das Tagesgeschehen an der Wiener Börse. Inhalte der Folge #832: - ATX fester, ATX TR auf Kurs erster 9000er-Close - Volumina bleiben mau - Aufträge für Strabag und Valneva, Änderung bei Immofinanz, Auszeichnungen für FACC und Uniqa, RBI/Oddo-Deal durch - RWT will Dividende aktivieren und sorgt für weiteren tollen Song - Ciao und Hallo bei Marinomed - schade um Valneva und CA Immo - weiter gehts im Podcast Links: - Börsepeople heute: Benjamin Levit http://www.audio-cd.at/people - kapitalmarkt-stimme.at daily voice Playlist auf spotify: http://www.kapitalmarkt-stimme.at/spotify - kapitalmarkt-stimme-Jingle-Mann Steve Kalen (neuer Song ist schon dabei): https://open.spotify.com/intl-de/artist/6uemLvflstP1ZerGCdJ7YU - Stockpicking Österreich: https://www.wikifolio.com/de/at/w/wfdrastil1? - http://www.boersentag.at ATX aktuell: https://www.wienerborse.at/indizes/aktuelle-indexwerte/preise-mitglieder/??ISIN=AT0000999982&ID_NOTATION=92866&cHash=49b7ab71e783b5ef2864ad3c8a5cdbc1 Die 2025er-Folgen der Wiener Börse Party (Co-verantwortlich Script: Christine Petzwinkler) sind präsentiert von Wienerberger, CEO Heimo Scheuch hat sich ebenfalls unter die Podcaster gemischt: https://open.spotify.com/show/5D4Gz8bpAYNAI6tg7H695E . Im Q1 ist die ÖBAG der Co-Presenter. Risikohinweis: Die hier veröffentlichten Gedanken sind weder als Empfehlung noch als ein Angebot oder eine Aufforderung zum An- oder Verkauf von Finanzinstrumenten zu verstehen und sollen auch nicht so verstanden werden. Sie stellen lediglich die persönliche Meinung der Podcastmacher dar. Der Handel mit Finanzprodukten unterliegt einem Risiko. Sie können Ihr eingesetztes Kapital verlieren. Und: Bewertungen bei Apple (oder auch Spotify) machen mir Freude: http://www.audio-cd.at/spotify http://www.audio-cd.at/apple 1969 full no Christian Drastil Comm.

Tue, 21 Jan 2025 12:17:00 +0000 https://jungeanleger.podigee.io/1943-wiener-borse-party-824-kontron-mit-gutem-ausblick-und-dementsprechendem-kursplus-stockpicking-osterreich-vs-joel-schwarzler c155ef021698b85da6d1ed4f9539cf0f Die Wiener Börse Party ist ein Podcastprojekt für Audio-CD.at von Christian Drastil Comm..Unter dem Motto „Market & Me“ berichtet Christian Drastil über das Tagesgeschehen an der Wiener Börse. Inhalte der Folge #824: - ATX TR nach 2 All-time-Highs hintereinander heute mit Korrektur - Kontron mit gutem Ausblick und dementsprechender Kursentwicklung - News zu Kontron, wienerberger, Porr, RBI, Valneva, Aktienkäufe bei Marinomed und Uniqa, Stresstest für Banken - in welcher Hinsicht ich mich mit Joel Schwärzler vergleiche - Vintage: Die Raus-aus-New-Economy-Umschichtung - weiter gehts im Podcast Links: - Börsepeople morgen: Crossover-Folge Zsolt Janos Christian Drastil http://www.audio-cd.at/people - kapitalmarkt-stimme.at daily voice Playlist auf spotify: http://www.kapitalmarkt-stimme.at/spotify - kapitalmarkt-stimme-Jingle-Mann Steve Kalen: https://open.spotify.com/intl-de/artist/6uemLvflstP1ZerGCdJ7YU - Stockpicking Österreich: https://www.wikifolio.com/de/at/w/wfdrastil1? - http://www.boersentag.at ATX aktuell: https://www.wienerborse.at/indizes/aktuelle-indexwerte/preise-mitglieder/??ISIN=AT0000999982&ID_NOTATION=92866&cHash=49b7ab71e783b5ef2864ad3c8a5cdbc1 Die 2025er-Folgen der Wiener Börse Party (Co-verantwortlich Script: Christine Petzwinkler) sind präsentiert von Wienerberger, CEO Heimo Scheuch hat sich ebenfalls unter die Podcaster gemischt: https://open.spotify.com/show/5D4Gz8bpAYNAI6tg7H695E . Im Q1 ist die ÖBAG der Co-Presenter. Risikohinweis: Die hier veröffentlichten Gedanken sind weder als Empfehlung noch als ein Angebot oder eine Aufforderung zum An- oder Verkauf von Finanzinstrumenten zu verstehen und sollen auch nicht so verstanden werden. Sie stellen lediglich die persönliche Meinung der Podcastmacher dar. Der Handel mit Finanzprodukten unterliegt einem Risiko. Sie können Ihr eingesetztes Kapital verlieren. Und: Bewertungen bei Apple (oder auch Spotify) machen mir Freude: http://www.audio-cd.at/spotify http://www.audio-cd.at/apple 1943 full no

Tue, 07 Jan 2025 10:45:00 +0000 https://jungeanleger.podigee.io/1908-wiener-borse-party-814-atx-schwacher-was-macht-denn-at-s-da-und-die-vorhaben-von-pierer-mobility-rbi-goes-bluechip dbed7a2d8b2b55dab2e880deb66ff209 Die Wiener Börse Party ist ein Podcastprojekt für Audio-CD.at von Christian Drastil Comm..Unter dem Motto „Market & Me“ berichtet Christian Drastil über das Tagesgeschehen an der Wiener Börse. Inhalte der Folge #814: - ATX schwächer, year-to-date wieder bei Null - Kapsch gesucht - was macht denn AT&S da? - Pierer Mobility bereitet 900 Mio. Euro-Finanzierung vor - Valneva in San Francisco, Oddo BHF In Lyon - TTTech News - RBI goes Bluechip - nur Chuck Norris schafft Minderheitsregierung mit 2/3 Mehrheit - weiter gehts im Podcast Links: - Börsepeople morgen: Valerie De Icco-Streibel, http://www.audio-cd.at/people - kapitalmarkt-stimme.at daily voice Playlist auf spotify: http://www.kapitalmarkt-stimme.at/spotify - kapitalmarkt-stimme-Jingle-Mann Steve Kalen: https://open.spotify.com/intl-de/artist/6uemLvflstP1ZerGCdJ7YU - 2h Wiener Börse Silvesterparty: https://audio-cd.at/page/podcast/6616 - Stockpicking Österreich: https://www.wikifolio.com/de/at/w/wfdrastil1? ATX aktuell: https://www.wienerborse.at/indizes/aktuelle-indexwerte/preise-mitglieder/??ISIN=AT0000999982&ID_NOTATION=92866&cHash=49b7ab71e783b5ef2864ad3c8a5cdbc1 Die 2025er-Folgen der Wiener Börse Party (Co-verantwortlich Script: Christine Petzwinkler) sind präsentiert von Wienerberger, CEO Heimo Scheuch hat sich ebenfalls unter die Podcaster gemischt: https://open.spotify.com/show/5D4Gz8bpAYNAI6tg7H695E . Im Q1 ist die ÖBAG der Co-Presenter. Risikohinweis: Die hier veröffentlichten Gedanken sind weder als Empfehlung noch als ein Angebot oder eine Aufforderung zum An- oder Verkauf von Finanzinstrumenten zu verstehen und sollen auch nicht so verstanden werden. Sie stellen lediglich die persönliche Meinung der Podcastmacher dar. Der Handel mit Finanzprodukten unterliegt einem Risiko. Sie können Ihr eingesetztes Kapital verlieren. Und: Bewertungen bei Apple (oder auch Spotify) machen mir Freude: http://www.audio-cd.at/spotify http://www.audio-cd.at/apple 1908 full no Christian Drastil Comm.

Thu, 19 Dec 2024 14:19:00 +0000 https://jungeanleger.podigee.io/1880-wiener-borse-party-806-atx-schwacher-morgen-verfallstag-im-janner-unter-strom-und-viele-abschiede-im-dezember 86da047a452c1d0a51c415402977e8e1 Die Wiener Börse Party ist ein Podcastprojekt für Audio-CD.at von Christian Drastil Comm..Unter dem Motto „Market & Me“ berichtet Christian Drastil über das Tagesgeschehen an der Wiener Börse. Inhalte der Folge #806: - ATX schwächer - Aufträge für Porr und Frequentis, News von Valneva, AT&S, AMAG, Aktienkäufe bei Palfinger - viele traurige Verluste dieser Tage, tolle Menschen sind von uns gegangen - im Jänner bin ich unter Strom - weiter gehts im Podcast Links: - Börsepeople morgen: Christoph Urbanek, http://www.audio-cd.at/people - kapitalmarkt-stimme-Jingle-Mann Steve Kalen: https://open.spotify.com/intl-de/artist/6uemLvflstP1ZerGCdJ7YU - Playlist 30x30 Finanzwissen pur für Österreich auf Spotify: https://open.spotify.com/playlist/3MfSMoCXAJMdQGwjpjgmLm - Stockpicking Österreich: https://www.wikifolio.com/de/at/w/wfdrastil1? ATX aktuell: https://www.wienerborse.at/indizes/aktuelle-indexwerte/preise-mitglieder/??ISIN=AT0000999982&ID_NOTATION=92866&cHash=49b7ab71e783b5ef2864ad3c8a5cdbc1 Die 2024er-Folgen der Wiener Börse Party (Co-verantwortlich Script: Christine Petzwinkler) sind präsentiert von Wienerberger, CEO Heimo Scheuch hat sich ebenfalls unter die Podcaster gemischt: https://open.spotify.com/show/5D4Gz8bpAYNAI6tg7H695E  . Im Q4 ist die ÖBAG der Co-Presenter. Risikohinweis: Die hier veröffentlichten Gedanken sind weder als Empfehlung noch als ein Angebot oder eine Aufforderung zum An- oder Verkauf von Finanzinstrumenten zu verstehen und sollen auch nicht so verstanden werden. Sie stellen lediglich die persönliche Meinung der Podcastmacher dar. Der Handel mit Finanzprodukten unterliegt einem Risiko. Sie können Ihr eingesetztes Kapital verlieren. Und: Bewertungen bei Apple (oder auch Spotify) machen mir Freude: http://www.audio-cd.at/spotify http://www.audio-cd.at/apple 1880 full no

Special guest Jean-Venable “Kelly” R. Goode, PharmD, BCPS, FAPhA, FCCP, Professor and Director of the Community-Based Residency Program at the Virginia Commonwealth University School of Pharmacy, join(s) us to talk about immunizations.Listen in as we discuss the latest COVID-19, influenza, and RSV vaccine recommendations and answer some common questions about giving vaccines.You'll also hear practical advice from TRC Editorial Advisory Board member, Stephen Carek, MD, CAQSM, DipABLM, the Program Director for the Prisma Health/USC School of Medicine Greenville Family Medicine Residency Program and Clinical Associate Professor at the University of South Carolina School of Medicine, Greenville.For the purposes of disclosure, Dr. Goode reports relevant financial relationships [vaccines] with Pfizer, Valneva (honorarium). The other speakers have nothing to disclose.  All relevant financial relationships have been mitigated.TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist's Letter, Pharmacy Technician's Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.Claim CreditThe clinical resources mentioned during the podcast are part of a subscription to Pharmacist's Letter and Prescriber Insights: Chart: Flu Vaccines for 2024-25 (United States)Chart: COVID-19 Vaccines 2024-25 (United States)FAQ: Preventing RSVResource Hub: Immunization Resource HubIf you're not yet a subscriber, find out more about our product offerings at trchealthcare.com. Follow, rate, and review this show in your favorite podcast app. Find the show on YouTube by searching for ‘TRC Healthcare' or clicking here. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com.

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:   The good — Pfizer, Valneva share phase 2 positive Lyme vax data  The bad — IN8bio axes workforce, halts trial  The ugly — AstraZeneca employees detained in China 

Vous ne savez pas dans quoi investir en Bourse ? Des gérants vous donnent des idées de valeurs, secteurs, matières premières ...

In this installment of Science Policy IRL, we explore another sector of science policy: private industry. Amanda Arnold is the vice president of governmental affairs and policy at Valneva, a private vaccine development company, where she works on policy for creating, manufacturing, and distributing vaccines that address unmet medical needs, such as for Lyme and Zika.  Arnold has worked in the science policy realm for over twenty years, first as a policy staffer for a US senator, then as a legislative liaison for the National Institutes of Health, and as a senior policy advisor at the Massachusetts Institute of Technology. Arnold talks to editor Megan Nicholson about the role industry plays in the science policy enterprise and what she has learned about the US innovation ecosystem from working across sectors.  Resources:  Read Amanda Arnold's Issues article, “Rules for Operating at Warp Speed,” to learn about how the government can work to rapidly respond to future crises.  Check out Ensuring an Effective Public Health Emergency Medical Countermeasures Enterprise and the Strategic National Stockpile reports to learn more about the issues Amanda thinks about in vaccine development policy.  Want to learn more about convergence? Check out these reports:  (1) The Convergence of Engineering and the Life Sciences (2013) (2) Convergence: Facilitating Transdisciplinary Integration of Life Sciences, Physical Sciences, Engineering, and Beyond (2014)  (3) Fostering the Culture of Convergence in Research (2019)

Que faire pour patienter jusqu'à la décision de la Fed, qui plus est une décision qui tombera post-clôture européenne ? Il est possible, au choix, de se lamenter sur les performances de Kering et d'Atos, de décortiquer les résultats d'un quartet de valeurs moyennes françaises emblématiques (Bénéteau, Virbac, Valneva, Haulotte) ou de prendre le pouls des investisseurs internationaux. Ou de tout passer en revue, ce qui sera le cas ce matin.

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Priority review vouchers for tropical diseases: Impact, distribution, effectiveness, and potential improvements, published by Rethink Priorities on January 5, 2024 on The Effective Altruism Forum. Suggested citation: Gosnell, G., Hu, J., Braid, E., & Hird, T. 2023. Priority review vouchers for tropical diseases: Impact, distribution, effectiveness, and potential improvements. Rethink Priorities. https://rethinkpriorities.org/publications/priority-review-vouchers. Funding statement: We thank Open Philanthropy for commissioning and funding this research report. The views expressed herein are not necessarily endorsed by Open Philanthropy. Editorial note The report evaluates the value and effectiveness of the United States' Tropical Disease Priority Review Voucher Program, which was initiated in 2007 to incentivize research and development for medical products targeting neglected tropical diseases. (While PRVs have since been legislated for purposes, we focus our attention on this application.) Specifically, we describe some of the program's history to date (e.g., past issuances, voucher sales/use dynamics, and evidence of gaming), the usage extent of PRV-awarded medical products, academic and anecdotal evidence of the program's incentive effect, and ways in which we think the program could be improved. We have tried to flag major sources of uncertainty in the report and are open to revising our views as more information becomes available. While preparing this report for publication, we learned that Valneva was awarded a PRV for developing the first Chikungunya vaccine in November 2023 (Dunleavy, 2023), but we did not incorporate this information in the report or associated spreadsheets. We are grateful for the invaluable input of our interviewees. Please note that our interviewees spoke with us in a personal capacity and not on behalf of their respective organizations. Executive summary We catalog information about the 13 issuances of Priority Review Vouchers (PRV) under the United States' Tropical Disease PRV Program and, for the seven cases with sufficient data, attempt to estimate the number of treatment courses per 1,000 relevant disease cases, or "use rate." Among the seven products with use rate estimates, we find three with high use rates (>100 courses per 1,000 cases), two have medium use rates (10-100), and two have low use rates (10 years, not all products marketed for that long achieve high use rates, and find diverse outcomes in use-rate trajectories, including sharp discontinuities and both upward and downward trends. Given that PRV recipients can either use or sell their voucher, we also explore the dynamics of how the PRVs' value is distributed among different types of players in the industry. We find that PRV sales proceeds go toward repayment for shareholders of small pharmaceutical companies or toward (promises of) further drug development for neglected tropical diseases. Large pharmaceutical companies that receive PRV awards tend to retain or use the voucher for faster FDA review of a profitable drug in their pipelines. Additionally, we review four academic studies that attempt to quantify the effectiveness of PRVs at inducing medical innovations for neglected tropical diseases. Based on their findings and our assessment of study quality, we think it is unlikely that the TD PRV Program had a large, consistent effect on R&D for tropical diseases, but that the results are potentially consistent with a small marginal effect. Additionally, there is historic anecdotal evidence of "gaming the system" - seeking a voucher for a drug that has already been developed and marketed outside of the US - though we think it is unlikely to continue to be an issue going forward given t...

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. ## The world's first CRISPR medicine, Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, has been approved in the UK for the treatment of sickle cell disease and beta thalassemia. However, a gene editing therapy like CRISPR may not be as simple as it seems. While Casgevy can mute the damaging symptoms of sickle cell disease, treatment may not be straightforward. Red Tree Venture Capital plans to expand into San Diego's biotech pipeline and build a competitor to Boston-area investors. The FDA has approved Augtyro, a new drug developed by Bristol Myers, for the treatment of lung cancer. Astellas has published a paper detailing a gene therapy study that led to patient deaths. The company is working with regulators to lift a clinical hold on the treatment.## The Biden administration has finalized a rule requiring nursing homes to disclose their ownership. CommonSpirit, a nonprofit operator, has started its 2024 fiscal year with a $738 million loss. CMS has proposed stricter network adequacy standards for plans sold in state-run ACA exchanges. Centene, a health insurer, has named Susan Smith as its new Chief Operating Executive. UnitedHealth is being sued for using an algorithm to deny care for Medicare Advantage members. There is an increasing trend of electronic health record (EHR) adoption, which has facilitated the rise of big data in healthcare.## The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has granted conditional marketing authorization for gene-edited therapy ExA-Cel, developed by Vertex Pharmaceuticals and CRISPR Therapeutics. This marks the world's first approval for a CRISPR-edited therapy. Bristol Myers Squibb's (BMS) drug Augtyro has received FDA approval to treat ROS1-positive non-small cell lung cancer (NSCLC). Astellas sees a path forward for its gene therapy AT132 despite four patient deaths in a clinical trial.## The traditional approach to health marketing is becoming inadequate and less effective compared to biotech and pharmaceutical marketers' expectations. Quad offers next-generation solutions that aim to deliver superior results at a lower cost. The text mentions that Quad has a downloadable resource called "next-gen solutions for health marketing" that covers various topics. Quad also offers advertising opportunities to reach over 96,000 biopharma industry executives.## Influencer marketing is growing at a faster rate than traditional paid social media and is projected to reach $21.2 billion worldwide by 2023. Top retailers are taking note of this trend and using it to shape their strategies for the future. The trendline highlights several examples of how brands are leveraging influencer marketing.## Cognizant's Life Sciences Manufacturing Practice offers resources such as web content, whitepapers, videos, and thought leadership articles on their website. They specialize in creating connected GMP manufacturing and lab systems using digital technology adoption and support.## An infographic discusses the factors and macro-trends that different types of medical device companies need to consider when developing a location strategy. The infographic highlights several macro-trends that companies should take into account when developing their manufacturing strategies.## Finance and procurement professionals in the healthcare industry are encouraged to stay ahead by embracing change and utilizing automation. There is an e-book available that provides tools for success and offers a custom demo for transforming operations management in healthcare organizations.## Novo Nordisk plans to invest $6 billion in expanding its manufacturing capabilities in Denmark. Valneva has received regulatory approval from the FDA for its chikungunya vaccine. The American Medical Association (AMA) has called for broader health insurance coverage f

VLA1553, commercially known as Ixchiq, has received USFDA clearance and will be launched in India — which has seen high number of chikungunya cases — after ‘regulatory talks with DCGI'.----more----Read full article here: https://theprint.in/health/worlds-1st-vaccine-against-chikungunya-primed-for-launch-in-india-says-french-drugmaker-valneva/1846509/

Last week, the FDA approved Eli Lilly's obesity drug Zepbound, creating an anticipated intense competition between it and Novo Nordisk's Wegovy. BioSpace's Greg Slabodkin, Tyler Patchen and Lori Ellis discuss the weight loss race and the future of this drug class. Plus, a quick recap on Valneva, the FDA's first Chikungunya vaccine approval.

Check out our free downloads at nascentmc.com: Implementing AMA Style – 8 Things to Get Right in Your Next Project Needs Assessments – 7 Essentials for Getting Funded Working With Your Medical Writer – 8 Ways to Get the Most out of Them See the full write ups for today's episode at  nascentmc.com/podcast Here are the highlights: The FDA has approved Zepbound (tirzepatide) for adults with obesity, allowing its use in individuals with a body mass index (BMI) of 30 or more, as well as overweight individuals (BMI of 27 or greater) with at least one weight-related condition. Tirzepatide, an agonist of GLP-1 and GIP, was shown to significantly reduce body weight when used in combination with a reduced-calorie diet and increased physical activity in clinical trials, but it may have adverse effects, including gastrointestinal issues and a potential link to medullary thyroid cancer. Ixchiq has become the first FDA-approved chikungunya vaccine for individuals aged 18 and older at increased risk of exposure to the chikungunya virus, which is primarily transmitted by mosquitoes. Chikungunya is a global health threat with symptoms including fever, joint pain, and rash, and severe joint pain that can last for months. The vaccine, while effective, may cause severe or prolonged chikungunya-like adverse reactions, and the manufacturer, Valneva, is required to conduct a postmarketing study to assess these risks. Fruzaqla (fruquintinib) has received FDA approval for patients with metastatic colorectal cancer (mCRC) who have undergone previous treatments, including various chemotherapy and targeted therapies. Fruquintinib, a kinase inhibitor of VEGFRs, demonstrated improvements in overall survival and progression-free survival in clinical trials, with consistent safety profiles. The approval was granted to Takeda, and the drug is also under review for marketing authorization in Europe. Adzynma (ADAMTS13, recombinant-krhn) has been approved by the FDA for congenital thrombotic thrombocytopenic purpura (cTTP), making it the first FDA-approved recombinant ADAMTS13 protein for this rare condition. cTTP results from a deficiency in ADAMTS13, leading to blood clot formation and severe bleeding episodes. Adzynma serves as prophylactic and on-demand treatment, with promising results in a phase 3 study, and its approval was granted to Takeda. Intro and outro music Garden Of Love by Pk jazz Collective

Special guests Lauren B. Angelo, PharmD, MBA from the Rosalind Franklin University of Medicine and Science and Jean-Venable “Kelly” R. Goode, PharmD, BCPS, FAPhA, FCCP from the Virginia Commonwealth University School of Pharmacy join us to talkabout influenza vaccines.Listen in as they review flu vaccine recommendations for the 2023-2024 influenza season.  You'll also hear practical advice from panelists on TRC's Editorial Advisory Board:Reid B. Blackwelder, MD, FAAFP, Associate Dean of Graduate and Continuing Medical Education and Professor of Family Medicine at East Tennessee State UniversityStephen Carek, MD, CAQSM, DipABLM, Clinical Assistant Professor of Family Medicine, Prisma Health/USC-SOMG Family Medicine Residency Program at the USC School of Medicine GreenvilleAndrea Darby Stewart, MD, Associate Director, Honor Health Family Medicine Residency Program and Clinical Professor of Family, Community & Occupational Medicine at the University of Arizona College of Medicine - PhoenixAnthony A. Donato, Jr., MD, MHPE, Associate Program Director, Tower Health System Internal Medicine Residency Program and Professor of Medicine at the Drexel University College of MedicineDouglas S. Paauw, MD, MACP, Professor of Medicine at the University of Washington School of MedicineFor the purposes of disclosure, Dr. Angelo reports relevant financial relationships [vaccines] with Moderna (honorarium); Pfizer (speakers bureau). Dr. Goode reports relevant financial relationships [vaccines] with Merck, Pfizer, Sanofi, Valneva (honorarium).The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist's Letter or Prescriber's Letter account and look for the title of this podcast in the list of available CE courses.The clinical resources mentioned during the podcast are part of a subscription to Pharmacist's Letter and Prescriber's Letter: Chart: Flu Vaccines for 2023-2024If you're not yet a Pharmacist's Letter or Prescriber's Letter subscriber, find out more about our product offerings at trchealthcare.com. Follow or subscribe, rate, and review this show in your favorite podcast app. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com.

Special guests Lauren B. Angelo, PharmD, MBA from the Rosalind Franklin University of Medicine and Science and Jean-Venable “Kelly” R. Goode, PharmD, BCPS, FAPhA, FCCP from the Virginia Commonwealth University School of Pharmacy join us to talk about respiratory syncytial virus (RSV) vaccines.Listen in as they review new RSV vaccine recommendations in adults age 60 years and older.  You'll also hear practical advice from panelists on TRC's Editorial Advisory Board:Reid B. Blackwelder, MD, FAAFP, Associate Dean of Graduate and Continuing Medical Education and Professor of Family Medicine at East Tennessee State UniversityStephen Carek, MD, CAQSM, DipABLM, Clinical Assistant Professor of Family Medicine, Prisma Health/USC-SOMG Family Medicine Residency Program at the USC School of Medicine GreenvilleAndrea Darby Stewart, MD, Associate Director, Honor Health Family Medicine Residency Program and Clinical Professor of Family, Community & Occupational Medicine at the University of Arizona College of Medicine - PhoenixAnthony A. Donato, Jr., MD, MHPE, Associate Program Director, Tower Health System Internal Medicine Residency Program and Professor of Medicine at the Drexel University College of MedicineFor the purposes of disclosure, Dr. Angelo reports relevant financial relationships [vaccines] with Moderna (honorarium); Pfizer (speakers bureau). Dr. Goode reports relevant financial relationships [vaccines] with Merck, Pfizer, Sanofi, Valneva (honorarium).The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist's Letter or Prescriber's Letter account and look for the title of this podcast in the list of available CE courses.If you're not yet a Pharmacist's Letter or Prescriber's Letter subscriber, find out more about our product offerings at trchealthcare.com. Follow or subscribe, rate, and review this show in your favorite podcast app. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com.

Porsche kommt mit Staatsfonds, GTA kommt mit Leaks und Valneva kommt ohne Impfstoff. Bei BioNTech und Moderna sorgt Biden für schlechte Stimmung und bei WIX sorgt Starboard für gute Stimmung. Warren Buffett liebt sie, der chinesische Warren Buffett (Li Lu) liebt sie, aber wird die Bank of America (WKN: 858388) ihrem Hype gerecht? Gas ist ein Problem. Aber Lithium-Eisenphosphat und zinnhaltige Glasbeschichtungen sind vielleicht die Zukunft und IBU-tec (WKN: A0XYHT) ist vielleicht ein Schnäppchen. Diesen Podcast der Podstars GmbH (Noah Leidinger) vom 20.09.2022, 3:00 Uhr stellt Dir die Trade Republic Bank GmbH zur Verfügung. Die Trade Republic Bank GmbH wird von der Bundesanstalt für Finanzaufsicht beaufsichtigt.

According to a recent study, more than 14% of the world's population probably has, or has had, tick-borne Lyme disease – an infection that can cause long and debilitating symptoms. That number is set to rise too, as climate and environment changes continue to increase tick populations and distribution. To help prevent some of these cases, pharmaceutical company Pfizer and biotech company Valneva will soon be testing a new vaccine against Lyme disease with 6,000 volunteers across Europe and in the US. Madeleine Finlay speaks to Dr Eoin Healy about what Lyme disease is and how the vaccine works, and hears from a special guest about their own experience of getting ill with the disease.. Help support our independent journalism at theguardian.com/sciencepod

Kann man sich durch eine Corona-Impfung mit dem Virus infizieren? Welche Nebenwirkungen haben die Impfstoffe Novavax und Valneva? Und wie ansteckend sind Geimpfte? Antworten von Professor Kekulé im Hörerfragen-Spezial.

Größter Hedgefonds der Welt wettet gegen Europa. JPMorgan wettet auf chinesische Tech-Aktien. Außerdem wettet Binance auf Ronaldo und die EU auf Valneva. Immer den perfekten Einstiegszeitpunkt treffen? Klingt geil. Ist fast unmöglich. Und gar nicht so rentabel, wie man denkt. Salate für 15 Dollar. 1.000 Filialen bis 2030. Und 100% Aufwärtspotenzial für die Aktie von Sweetgreen (WKN: A3C7N2). Diesen Podcast der Podstars GmbH (Noah Leidinger) vom 24.06.2022, 3:00 Uhr stellt Dir die Trade Republic Bank GmbH zur Verfügung. Die Trade Republic Bank GmbH wird von der Bundesanstalt für Finanzaufsicht beaufsichtigt.

Franck Grimaud, PDG de Valneva, était l'invité de Christophe Jakubyszyn dans Good Morning Business, ce mardi 21 juin. Il s'est penché sur l'accord trouvé sur le vaccin contre la maladie de Lyme sur BFM Business. Retrouvez l'émission du lundi au vendredi et réécoutez la en podcast.

Ce mardi 21 juin, Sandra Gandoin et Christophe Jakubyszyn ont reçu Jean-Louis Bourlanges, député MoDem des Hauts-de-Seine, Franck Grimaud, PDG de Valneva, Stéphane Bénichou, associé du cabinet "In The Board Room", et Frédéric Plais, CEO et co-fondateur de Platform.sh, dans l'émission Good Morning Business sur BFM Business. Retrouvez l'émission du lundi au vendredi et réécoutez la en podcast.

Die Erzeugerpreise steigen schneller als je zuvor, aber die Börsen juckt's nicht. Vielmehr jucken sie Riesen-Jets bei Lufthansa, Pfizers Zockerei mit Valneva-Aktien, Call-Center-Fusionen und ein stabiler Bitcoin. United Natural Foods (WKN: 903615) ist der größte Bio-Händler Amerikas, die stabilste Aktie vergangener Bärenmärkte und genau deshalb einen Blick wert. Die Buchbranche boomt. Erst der Corona-Rückenwind. Dann der BookTok-Hype auf TikTok. Kein Wunder, dass der Harry-Potter-Verlag Bloomsbury (WKN: 460093) selbst in 2022 Rendite liefert. Diesen Podcast der Podstars GmbH (Noah Leidinger) vom 21.06.2022, 3:00 Uhr stellt Dir die Trade Republic Bank GmbH zur Verfügung. Die Trade Republic Bank GmbH wird von der Bundesanstalt für Finanzaufsicht beaufsichtigt.

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Nando Sommerfeldt und Holger Zschäpitz über den Wahnsinn beim Weizen, einen geplatzten Impfstoff-Deal, großzügige Gehaltserhöhungen bei Microsoft und sie prüfen, ob die Hedgefonds-Profis die Krise besser meistern. Außerdem geht es um Valneva, Datadog, Zscaler, Okta, Crowdstrike, Twitter, Tesla, Netflix, Carvana, Ark Innovation (WKN: A14Y8H), Amazon, Meta, Coinbase, Spotify, IHS Markit, Activision Blizzard, Zynga, Sentinel One, Shell, Haliburton, Schlumberger, ConocoPhilips, EQT, Apollo, HP, Ally Financial, Paramount Global, McKesson, Wells Fargo, Alibaba, Baidu, Pinduodo, Netease, Pindoudou, Tencent, iShares MSCI China Tech ETF (WKN: A3CU00), UBS Lux Fund Solutions - Solactive China Technology (WKN: A2QJ9G). Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++Werbung+++ Hier geht's zur App: Scalable Capital ist der Broker mit Flatrate. Unbegrenzt Aktien traden und alle ETFs kostenlos besparen – für nur 2,99 € im Monat, ohne weitere Kosten. Und jetzt ab aufs Parkett, die Scalable App downloaden und loslegen. Hier geht's zur App: https://bit.ly/3abrHQm Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Ever met a dog that's anti-vax? Probably not. And that's why they can be protected from dangerous tick bites, but we can't (yet).

Franck Grimaud, directeur général de Valneva, était l'invité de Sandra Gandoin et Guillaume Paul dans Good Morning Business, ce vendredi 15 avril 2022. Ils sont revenus sur la mise sur le marché britannique de Valneva, sixième vaccin contre le Covid au Royaume-Uni, sur BFM Business. Retrouvez l'émission du lundi au vendredi et réécoutez la en podcast.

Ce vendredi 15 avril, Sandra Gandoin et Christophe Jakubyszyn ont reçu Alexandre Fitussi, cofondateur et Président de Beanstock, Guy Mamou-Mani, coprésident d'Open, Nordine Hachemi, PDG chez Kaufman & Broad, et Franck Grimaud, directeur général Valneva, dans l'émission Good Morning Business sur BFM Business. Retrouvez l'émission du lundi au vendredi et réécoutez la en podcast.

英國COV-BOOST大型第三劑混打試驗終於發表！等好久了！這是英國在九月做出其加強針以mRNA疫苗為主政策主要的根據。 1.這是在英國執行的臨床試驗，在AZAZ和BNTBNT第二劑至少10~12週後，用七種疫苗來當第三針的效果。包括了AZ，BNT，莫德納，Novavax，滅活疫苗Valneva，德國的Curevac，嬌生。其中BNT，Novavax, Valneva還有測試半劑量。每組約100人，總共受試者達2883人。 2.很可惜，這裡莫德納用的是全劑量，不是半劑量。莫莫減半是廠商自己做的臨床試驗，COV-boost則是英國自己規劃的。 3.BNTBNT組打滅活Valneva抗體上不太來。所以AZAZ後可打滅活，mRNA後打滅活似乎效果不佳。 4.其他任何組合，抗體都會上來，只是倍數高低的問題。mRNA疫苗抗體是上來最高的，全量莫德納＞全量BNT＞半量BNT。Novavax有一定的效果，但沒有mRNA效果好。 5.不難理解為何英國九月會做出AZAZ後以mRNA疫苗為加強針首選的決定，抗棘蛋白抗體可增加16~32倍。Novavax可以增加約8.75倍，其他疫苗則效果有限。三劑AZ雖然抗體可以微升3倍，但T細胞免疫方面幾乎沒有再進步的空間了。 6.有趣的是，BNT減半抗體其實沒差太多，但可減少些不良反應。所以減量BNT做為第三針也許是個選擇。 7.AZAZAZ連打三針雖可讓抗體再上來些，但細胞免疫幾乎無法再增加。BNTBNTAZ，相比於BNTBNT 加其他疫苗，細胞免疫似乎也沒有太大優勢。BNT兩劑後施打mRNA疫苗，也是可以提升細胞免疫的喔。 英國COV-BOOST大型第三劑混打試驗發表！兩劑AZ BNT後該打什麼？ https://linshibi.com/?p=39836 Omicron變種病毒懶人包 傳染力 重症 疫苗有效性 要打加強針嗎？ https://linshibi.com/?p=39815 小額贊助支持本節目： https://pay.firstory.me/user/linshibi Powered by Firstory Hosting

New Covid vaccine from Valneva produces stronger immune response when compared to AstraZeneca, the French company reports, with no severe cases of Covid-19 seen in either group. And new positive research on lateral flow tests. Plus guest Graham Easton discusses the urgent need for teaching climate and environmental health in medical schools. Presenter: Claudia Hammond Producer: Erika Wright (Picture: Coronavirus vaccine vials on a laboratory shelf. Photo credit: Joao Paulo Burini/Getty Images.)